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213 Arterial switch with full-flow cardiopulmonary bypass and limited
circulatory arrest: Neurodevelopmental outcome
Tom R. Karl, MD, Suzanne Hall, RN, Geoff Ford, MD, Elaine A. Kelly, MS,
Christian P. R. Brizard, MD, Roger B. B. Mee, FRACS, Robert G. Weintraub, MB, BS,
Andrew D. Cochrane, FRACS, and David Glidden, PhD, San Francisco, Calif; Melbourne,
Australia; and Cleveland, Ohio
Neonatal cardiac surgery has been associated with unfavorable neurodevelopmental events. We
investigated a patient cohort operated on predominantly with full-flow CPB as the major
support stragety for neonatal arterial switch operations. On the basis of our results, continued
application of full-flow CPB is justified, with the proviso that further investigation is required.
223 Changes in cerebral and somatic oxygenation during stage 1 palliation of
hypoplastic left heart syndrome using continuous regional cerebral perfusion
George M. Hoffman, MD, Eckehard A. Stuth, MD, Robert D. Jaquiss, MD,
Patrick L. Vanderwal, MSP, Susan R. Staudt, MD, Todd J. Troshynski, MD,
Nancy S. Ghanayem, MD, and James S. Tweddell, MD, Milwaukee, Wis
Cerebral oxygenation decreases and somatic oxygenation increases after stage 1 palliation of
hypoplastic left heart syndrome with deep hypothermic CPB and continuous cerebral perfusion.
234 Intraoperative device closure of perimembranous ventricular septal defects
without cardiopulmonary bypass: Preliminary results with the
perventricular technique
Zahid Amin, MD, David A. Danford, MD, John Lof, MS, Kim F. Duncan, MD, and
Stacey Froemming, BS, Omaha, Neb
Perimembranous ventricular septal defects were closed in an animal model by using a new
perventricular technique. The defects were closed with the Amplatzer membranous occluder
under echocardiographic guidance while the heart was beating. Complete closure was achieved
without any complications.
242 Blood group incompatibility and accelerated homograft fibrocalcifications
Jan T. Christenson, MD, FETCS, Dominique Vala, MD, Jorge Sierra, MD,
Maurice Beghetti, MD, and Afksendiyos Kalangos, MD, FETCS, Geneva, Switzerland
Accelerated homograft fibrocalcification following RVOT reconstruction using cryopreserved
homografts is more often observed in patients 3 years old and younger when blood group
incompatibility between homograft receiver and donor is not respected. Freedom from
fibrocalcification at 8 years was 95.2% for blood groupcompatible grafts and 72.9% for
blood groupincompatible grafts.
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